Meta-Analysis of Randomized Controlled Trials on the Efficacy of Di'ao Xinxuekang Capsule and Isosorbide Dinitrate in Treating Angina Pectoris by Jia, Yongliang et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meta-Analysis of Randomized Controlled Trials on the Efficacy of
Di'ao Xinxuekang Capsule and Isosorbide Dinitrate in Treating
Angina Pectoris
Citation for published version:
Jia, Y, Chen, C, Ng, C & Leung, S 2012, 'Meta-Analysis of Randomized Controlled Trials on the Efficacy of
Di'ao Xinxuekang Capsule and Isosorbide Dinitrate in Treating Angina Pectoris' Evidence-Based
Complementary and Alternative Medicine, vol. 2012, pp. 1-8. DOI: 10.1155/2012/904147
Digital Object Identifier (DOI):
10.1155/2012/904147
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Evidence-Based Complementary and Alternative Medicine
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 904147, 8 pages
doi:10.1155/2012/904147
Research Article
Meta-Analysis of Randomized Controlled Trials on the Efficacy
of Di’ao Xinxuekang Capsule and Isosorbide Dinitrate in Treating
Angina Pectoris
Yongliang Jia,1, 2 Cong Chen,1, 2 Choi-San Ng,1, 2 and Siu-Wai Leung1, 2, 3
1 State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Taipa 999078, Macau
2 Institute of Chinese Medical Sciences, University of Macau, Taipa 999078, Macau
3 BIGHT Laboratory, School of Informatics, University of Edinburgh, Edinburgh EH8 9AB, UK
Correspondence should be addressed to Siu-Wai Leung, siu@inf.ed.ac.uk
Received 1 November 2011; Revised 20 December 2011; Accepted 20 December 2011
Academic Editor: Gerhard Litscher
Copyright © 2012 Yongliang Jia et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. Randomized controlled trials (RCTs) on di’ao xinxuekang capsule (XXK) in treating angina pectoris were published
only in Chinese and have not been systematically reviewed particularly for comparing XXK with isosorbide dinitrate (ISDN). This
study aims to provide a comprehensive PRISMA compliant and internationally accessible systematic review and meta-analysis to
evaluate the eﬃcacies of XXK and ISDN in treating angina pectoris. Methods. The RCTs published between 1989 and 2011 on
XXK and ISDN in treating angina pectoris were selected according to specific criteria. Meta-analysis was performed to evaluate
the symptomatic (SYMPTOMS) and electrocardiographic (ECG) improvements after treatment. Odds ratios (OR) were used to
measure eﬀect sizes. Subgroup analysis, sensitivity analysis, and metaregression were conducted to evaluate the robustness of the
results. Results. Seven RCTs with 550 participants were eligible. Overall ORs for comparing XXK with ISDN were 4.11 (95% CI :
2.57, 6.55) in SYMPTOMS and 2.37 (95%CI : 1.46, 3.84) in ECG. Subgroup analysis, sensitivity analysis, andmetaregression found
no significant dependence of overall ORs upon specific study characteristics. Conclusion. The meta-analysis of eligible but limited
RCTs demonstrates that XXK seems to be more eﬀective than ISDN in treating angina pectoris. Further RCTs of high quality are
warranted to be conducted for update of the results of this meta-analysis.
1. Introduction
Ischemic heart disease, an imbalance coronary blood flow
and myocardial requirement [1], usually has symptomatic
discomfort in the chest, that is, angina pectoris [2], due
to coronary insuﬃciency and myocardium ischemia and
hypoxia [3]. Nitrates, calcium channel blockers, beta-recep-
tor blockers are common drugs for treating angina pectoris
[4]. Isosorbide dinitrate (ISDN) is one of the most eﬀective
and frequently used nitrates for treating angina pectoris
[3, 5]. Di’ao xinxuekang (XXK) capsule is a second-class new
drug of China for treating angina pectoris [6]. The main
components of XXK are extracted from the rhizomes of Dio-
scorea panthaica Prain et Burkill and Dioscorea nipponica
Makino [7].
Randomized controlled trials (RCTs) on treatments of
angina pectoris found that XXK was more eﬀective than
aspirin [8] and more eﬀective than some Chinese medicinal
formulations including compound danshen, guanxin suquan
pills, and danshen dripping pills [9, 10]. A previous sys-
tematic review published in 2010 [11] suggested that XXK
were more eﬀective than danshen tablet but did not cite any
eligible RCT and did not report any subgroup or sensitivity
analysis. XXK and danshen dripping pills are two popular
Chinese medicinal products often compared with ISDN in
treating angina pectoris [12–15]. A recent systematic review
published in 2011 [16] indicated that danshen dripping
pills was more eﬀective than ISDN. Furthermore, there is
no systematic review or meta-analysis of RCTs comparing
XXK with conventional nitrates such as ISDN. As such,
it is not clear about whether XXK is more eﬀective than
ISDN in treating angina pectoris. This study aims to conduct
a comprehensive, PRISMA-compliant [17], internationally
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accessible, and timely meta-analysis, with subgroup and
sensitivity analyses of RCTs to compare the eﬃcacies of XXK
and ISDN in treating angina pectoris.
2. Methods
2.1. Study Selection Criteria. RCTs published in Chinese or
English between 1989 (i.e., the year of XXK launch) and 2011
on comparing XXK with ISDN in treating angina pectoris
were screened. Inclusion criteria were as follow: (a) partici-
pants were suﬀering from and being treated for angina pec-
toris; (b) the study was claimed to be an RCT; (c) the study
compared XXK with ISDN in eﬃcacy; (d) duration of treat-
ment (follow-up period) was at least four weeks.
Exclusion criteria were as follow: (a) duplicated or redun-
dant study; (b) XXK was used in combination with other
drugs; (c) ISDN was used in combination with other drugs;
(d) the study did not include symptomatic (SYMPTOMS)
improvement as the major outcome.
2.2. Search Strategies. RCT reports published between the
1989 and 2011 were searched from databases including China
National Knowledge Infrastructure (CNKI), WanFang Data,
China Master Theses Full-text Database (CMTD), China
Doctor Dissertations Full-text Database (CDMD), Medline,
PubMed, Cochrane Library, ScienceDirect and EMbase. The
last search was performed on 22 August 2011.
The search strategy was formulated mainly for searching
xinxuekang because of few publications on the drug. For in-
stance, WanFang Data was searched with such a simple query
as: ((“guanxinbing (heart disease)” in title or “xinjiaotong
(angina pectoris)” in title) and “xinxuekang” in abstract).
The exact search strategies and query syntax were slightly ad-
justed according to the users’ instructions from diﬀerent
databases.
2.3. Study Selection. Two reviewers (Y. Jia and C. Chen)
independently screened all retrieved studies according to
the eligibility criteria. Disagreement between reviewers was
resolved by consensus. A flow diagram of study selection was
generated according to the PRISMA requirements [17].
2.4. Data Extraction. Two reviewers (Y. Jia and C. Ng) inde-
pendently extracted data items comprised (a) publication
year; (b) number of authors; (c) trial dates; (d) baseline com-
parizson of participants between groups; (e) sample size; (f)
outcome measures; (g) dosage and treatment duration; (h)
incidence of adverse events (AE).
2.5. Quality Assessment of Included Studies. Two reviewers
(Y. Jia and C. Chen) independently assessed the quality of
the included studies according to the Jadad scale [18], the M
scale [16] and the Cochrane risk of bias tool [19]. The Jadad
scale focused on three criteria including “randomization,”
“blinding,” and “dropouts” for assessing the quality of RCT.
The M scale was modified from the Jadad scale with two
additional criteria “baseline comparison of participants” and
“adverse event report.” The Cochrane risk of bias tool was
designed for more detailed assessment including criteria for
(a) allocation concealment, (b) blinding of participants, (c)
personnel and outcome assessment, (d) incomplete outcome
data, (e) selective reporting, and (f) other biases [19].
2.6. Criteria for Symptomatic and ECG Improvements. Eﬀec-
tive symptomatic improvements should achieve at least 50%
(basic) or 80% (significant) reduction in frequency of feel-
ing angina chest pain. Eﬀective ECG improvements should
achieve at least 0.05mV lowering at ST segment in ECG
(basic) or nearly normal (significant) ECG during an exercise
test as suggested in the ACC/AHA guideline [3].
2.7. Meta-Analysis. Eﬀect sizes were presented by odds ratios
(OR) [20] and 95% confidence intervals (CI) [21]. Overall
meta-analysis and subgroup analysis employed the random-
eﬀects model because the homogeneity of the studies could
not be guaranteed. Heterogeneity among studies was assessed
by chi-squared (χ2) and I-squared (I2) [22].
2.8. Subgroup and Sensitivity Analysis. Subgroup analysis was
conducted to evaluate the overall eﬀects in possible sub-
groups which were grouped according to the characteristics
of the studies, including year of publication, number of
authors, follow-up period, sample sizes, study periods,
quality of the studies (M score), and improvements in SYMP-
TOMS and ECG. Mann-Whitney-Wilcoxon test was used to
analyze the diﬀerence between subgroups. Sensitivity analy-
ses were performed after excluding some studies to assess the
influence of such studies on the overall result of this meta-
analysis.
2.9. Metaregression and Risk of Bias across Studies. Funnel
plots [23], Begg’s rank correlation test [24], and Egger’s linear
regression test [25] were employed to assess the publication
bias. Metaregression [26] was conducted to find the possible
relationship between the eﬃcacy and the factors such as sam-
ple sizes, M score, years of publication, and quality of RCTs.
2.10. Adverse Events. AEs of RCTs including nonreported
AEs, types and frequency of AEs reported were surveyed for
incidence of AEs during XXK and ISDN treatments.
2.11. Statistical Analysis. Meta-analysis and forest plot gener-
ation were performed with Review Manager 5 [27]. Metare-
gression and funnel plot generation was conducted with
Stata software version 11 (StataCorp LP, USA). Statistical
software R [28] was used to perform conventional statis-
tical analysis, including Spearman correlation and Mann-
Whitney-Wilcoxon unpaired two-sample test. P values lower
than 0.05 were considered statistically significant.
3. Results
3.1. Study Selection. The process of study selection was
depicted in Figure 1. The database search found 435 records,
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Figure 1: Process of searching and screening studies.
Table 1: Summary of the included studies evaluating the eﬃcacy of XXK in treating angina pectoris.
Study
No. of
authors
Trail
date
Sample
size
Follow-up
period
Comparable AEs
Outcome
measures
XXK daily
dosage
ISDN daily
dosage
Jadad
score
M score
Zeng et al. [29] 6 0 34 28 days 1 1 SYM, ECG 6 pills 40mg 2 4
Dai [30] 1 1 120 28 days 0 0 SYM 6 pills 30mg 2 2
Hu [31] 1 0 84 28 days 1 1 SYM, ECG 6 pills 30mg 2 4
Li and Zhang [34] 2 1 60 28 days 0 1 SYM 6 pills 60mg 2 3
Qu [32] 1 1 60 28 days 1 0 SYM, ECG 6 pills 30mg 2 3
Shen [33] 1 1 132 28 days 0 1 SYM, ECG 6 pills 30mg 2 3
Zhu et al. [35] 5 1 60 28 days 1 0 SYM, ECG 6 pills 30mg 2 3
XXK is di’ao xinxuekang capsule; ISDN is isosorbide dinitrate; SYM is SYMPTOMS; ECG is electrocardiogram; AEs is adverse events; Numbers 1 and 0 in
“Trial date” mean that study reported or did not report the trial date, respectively; Numbers 1 and 0 in “Comparable” mean that the study reported the
comparability between the experiment and control groups (1) or the study did not report that (0).
including 209 records from CNKI, 190 records from Wan-
Fang Data, 24 records from CMTD, 6 records from CDMD, 2
records from PubMed, 2 records fromMedline, and 2 records
from the Cochrane Library. According to the prespecified
selection criteria described in the section Methods, only
seven studies [29–35] were found eligible for further quality
assessment and meta-analysis.
3.2. Study Characteristics. Table 1 lists the main characteris-
tics of the included studies. All of the studies were published
in Chinese language between 1993 and 2007 with a total of
550 participants. The mean sample size was 78.6 (median =
60.0; 95% CI: 52.2, 105.0). The follow-up periods were all
28 days. The daily dosage of XXK was 6 pills in all studies.
The daily dosages of ISDN were 30mg in five studies, 40mg
and 60mg in the other two studies. All seven included studies
reported SYMPTOMS changes as outcome measures while
five studies [29, 31–33, 35] also reported ECG changes.
3.3. Quality Assessment of Included Studies. Table 1 lists the
results of quality assessment according to the Jadad and
M scale. All included studies were scored 2 according to
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Study or subgroup
XXK
Events
ISDN
Events
Odds ratio
M-H, random, 95% CI
6.7% 2.15 [0.36, 12.76]
59 66 46 66 22.3%
12 16 14 18
Total events
Odds ratio
M-H, random, 95% CI
ISDN XXK
0.02 0.1 1 10 50
Total Total Weight
Dai, 2000 45 60 18 60 29.6% 7 [3.13, 15.64]
Hu, 2009 38 43 25 41 16.1% 4.86 [1.58, 14.97]
Li, 2000
Qu, 2006
Shen, 1993
Zeng, 1996
Zhu, 2007
Total (95% CI)
237
Heterogeneity: = 0.02; = 6.36, df = 6 (P = 0.38); I2 = 6%
Test for overall eﬀect: Z = 5.93 (P < 0.00001)
29 30 24 30 4.5% 7.25 [0.82, 64.46]
28 30 26 30
3.66 [1.43, 9.41]
26 30 19 30 12.5% 3.76 [1.04, 13.65]
8.4% 0.86 [0.18, 4.19]
275 275 100% 4.11 [2.57, 6.55]
172
τ2 χ2
Figure 2: Forest plot of outcome measure SYMPTOMS.
Study or subgroup
XXK
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Figure 3: Forest plot of outcome measure ECG.
the Jadad scale (between 0 and 5 points), in consistency with
the average quality of Chinese RCTs [36].
According to M scale, four RCTs scored three, two RCTs
scored two, and one RCT scored one. Four included studies
[29, 31, 32, 35] reported baseline comparison of participants
in experiment and control group. Three included studies [30,
32, 35] did not report AEs. One included study [29] reported
types of AEs. Three included studies [31, 34, 35] reported
types and number of AEs.
Cochrane risk of bias tool also gave similar ratings, that
is, (a) unclear bias in random sequence generation; (b) high
bias in allocation concealment; (c) high bias in blinding of
participants; (d) personnel and outcome assessment; (e) low
bias in incomplete outcome data; (f) low bias in selective
reporting; (g) unclear bias in other bias.
3.4. Individual Studies and Their Synthesis. As shown in
Figure 2, the overall OR of SYMPTOMS was 4.11 (95% CI =
2.57–6.55, Z = 5.93, P < 0.00001) with a heterogeneity
(τ = 0.02, I2 = 6%, P = 0.38) among the seven studies
with SYMPTOMS outcome. Figure 3 shows that the overall
OR of ECG was 2.37 (95% CI = 1.46–3.84, Z = 3.50,
P = 0.0005) with a heterogeneity (τ = 0, I2 = 0%, P =
0.57) among the five studies with ECG outcome. Both the
ORs of SYMPTOMS and ECG indicated that XXK is more
eﬀective than ISDN in treating angina pectoris. The overall
OR of SYMPTOMS was bigger than that of ECG although
the correlation in ORs between SYMPTOMS and ECG was
not statistically significant (P = 0.6833).
3.5. Subgroup and Sensitivity Analysis. Based on study char-
acteristics including M score (≤3 or >3), years of publication
(before or after 1 January 2005), number of authors (1
or >1), dates of trial (reported or non-reported), baseline
comparison of participants (yes or no), sample sizes (<78
or ≥78), and reports of AEs (yes or no), subgroup analysis
or sensitivity analysis were performed and their results are
shown in Tables 2 and 3. Wilcoxon test for comparing the
ORs between subgroups in terms of SYMPTOMS and ECG
found no statistically significant diﬀerences.
When the improvements in SYMPTOMS were raised to
a significant level from the basic level, the results remain
eﬀective and statistically significant (OR = 1.83, 95% CI =
1.20–2.82, Z = 2.77, P = 0.006).The overall ECG OR
decreased from 2.37 to 1.60 (95% CI = 0.98–2.60, Z = 1.88,
P = 0.06) with a heterogeneity (τ = 2.38, I2 = 0%, P = 0.67).
The results indicated there was not heterogeneity. Likewise,
results of Spearman correlation analysis indicated there was
not statistical significance (P = 0.95) between them.
3.6. Metaregression. Table 4 shows the results of meta-
regression between logOR and study characteristics. As
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Table 2: Subgroups and sensitivity analysis based on ORs of SYMPTOMS outcomes.
Group
No. of
studies
No. of
participants
OR Wilcoxon test 95% CI Z P (eﬀect) I2 χ2 P (het)
M score ≤3 5 432 4.76 W = 7 2.85, 7.95 5.96 <0.00001 0% 2.21 0.70
>3 2 118 2.24 P = 0.4386 0.41, 12.17 0.94 0.35 67% 3.06 0.08
Sample size <78 4 214 2.49 W = 4 1.09, 5.68 2.17 0.03 3% 3.09 0.38
≥78 3 336 5.22 P = 0.4795 3.05, 8.93 6.03 <0.00001 0% 1.07 0.59
No. of authors 1 4 396 4.85 W = 6 2.90, 8.11 6.01 <0.00001 0% 1.94 0.58
>1 3 154 2.61 P = 1 0.82, 8.36 1.62 0.11 35% 3.06 0.22
Publication year <2005 4 346 3.84 W = 7 1.65, 8.93 3.12 0.002 47% 5.71 0.13
≥2005 3 204 3.82 P = 0.7237 1.78, 8.21 3.44 0.0006 0% 0.58 0.75
Trial date Reported 5 432 4.76 W = 7 2.85, 7.95 5.96 <0.000
01
0% 2.21 0.70
Not
reported
2 118 2.24 P = 0.4386 0.41, 12.17 0.94 0.35 67% 3.06 0.08
Comparable Reported 4 238 2.83 W = 2 1.36, 5.89 2.78 0.005 10% 3.35 0.34
Not
reported
3 312 5.45 P = 0.1573 3.02, 9.83 5.64 <0.00001 0% 1.12 0.57
AEs Reported 4 310 3.30 W = 6 1.58, 6.88 3.18 0.0001 21% 3.78 0.29
Not
reported
3 240 5.17 P = 1 2.74, 9.78 5.06 <0.00001 0% 1.71 0.43
Improvement >50% 7 550 4.11 W = 7 2.57, 6.55 5.93 <0.00001 6% 6.36 0.38
>80% 5 370 1.83 P = 0.2506 1.20, 2.82 2.77 0.006 0% 1.10 0.89
CI is confidence interval. Mann-Whitney-Wilcoxon test was performed on ORs of SYMPTOMS. Z and P (eﬀect) evaluated the statistics of overall eﬀect; I2,
χ2, and P (het) were computed to assess heterogeneity.
Table 3: Subgroups and sensitivity analysis based on ORs of ECG outcomes.
Group
No. of
studies
No. of
participants
OR
Wilcoxon
test
95% CI Z P (eﬀect) I2 χ2 P (het)
M score ≤3 3 252 2.73 W = 4 1.52, 4.91 3.35 0.0008 0% 0.24 0.89
>3 2 118 1.65 P = 0.5637 0.49, 5.57 0.8 0.42 49% 1.98 0.16
Sample size <78 3 154 1.71 W = 2 0.77, 3.84 1.31 0.19 0% 1.93 0.38
≥78 2 216 2.84 P = 0.5637 1.56, 5.20 3.39 0.0007 0% 0 0.99
No. of authors 1 3 276 2.91 W = 6 1.65, 5.14 3.69 0.000 2 0% 0.05 0.97
>1 2 94 1.39 P = 0.0833 0.54, 3.55 0.68 0.5 4% 1.05 0.31
Publication year <2005 2 166 1.75 W = 1 0.54, 5.74 0.93 0.35 60% 2.47 0.12
≥2005 3 204 2.69 P = 0.2482 1.29, 5.60 2.63 0.008 0% 0.24 0.89
Trial date Reported 2 118 1.65 W = 2 0.49, 5.57 0.8 0.42 49% 1.98 0.16
Not reported 3 252 2.73 P = 0.5637 1.52, 4.91 3.35 0.0008 0% 0.24 0.89
Comparable Reported 4 238 2.06 W = 2 1.08, 3.93 2.19 0.03 0% 2.48 0.48
Not reported 1 132 2.83 P = 1 1.37, 5.85 2.81 0.005 NA NA NA
AEs Reported 3 250 2.22 W = 2 1.14, 4.32 2.33 0.02 25% 2.66 0.26
Not reported 2 120 2.54 P = 0.5637 0.94, 6.90 1.83 0.07 0% 0.21 0.65
Improvement >50% 5 370 2.37 W = 14 1.46, 3.84 3.5 0.0005 0% 2.90 0.57
>80% 5 370 1.60 P = 0.7540 0.98, 2.60 1.88 0.06 0% 2.38 0.67
CI is confidence interval. NA is not available; Mann-Whitney-Wilcoxon test was performed on ORs of ECG. Z and P (eﬀect) evaluated the statistics of overall
eﬀect; I2, χ2, and P (het) were computed to assess heterogeneity.
the results of metaregression were not statistically significant,
there seems to be no obvious correspondence of the ef-
ficacy to any study characteristic.
3.7. Risk of Bias across Studies. Publication biases were
assessed by funnel plots (Figure 4), which found no obvious
asymmetry for SYMPTOMS and ECG. The Begg’s test
(SYMPTOMS: Z = −0.75, P = 0.453; ECG: Z = −0.98,
P = 0.327) and the Egger’s test (SYMPTOMS: t = −1.15,
P = 0.301; ECG: t = −0.70, P = 0.536) also found no stati-
stically significant publication bias.
3.8. Adverse Events. Three studies [30, 32, 35] of seven in-
cluded studies did not report AEs. The AEs among 155 parti-
cipants in the studies with AE reports were mainly headache
and dizziness. A study [29] reported that the AE incidence of
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Table 4: Metaregression of basic characteristics of RCTs and ORs of SYMPTOMS and ECG outcomes.
LogOR No. of RCTs No. of participants Factor tested Coeﬃcient t P
Publication year 0.0200 0.43 0.685
No. of authors −0.2106 −1.63 0.165
Trail date 0.5646 1.00 0.365
SYMPTOMS 7 550 Sample size 0.0069 1.52 0.190
Comparable −0.6369 −1.38 0.227
AEs −0.4280 −0.89 0.412
M score −0.4829 −1.56 0.180
Publication year 0.0097 0.26 0.809
No. of authors −0.1796 −1.46 0.239
Trail date 0.4354 0.83 0.469
ECG 5 370 Sample size 0.0073 1.10 0.354
Comparable −0.3195 −0.64 0.565
AEs −0.0911 −0.16 0.886
M score −0.4354 −0.83 0.469
Metaregression was conducted by residual (restricted) maximum likelihood (REML) with Knapp-Hartung modification.
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Figure 4: Funnel plots of (a) the included studies with SYMPTOMS data and (b) the included studies with ECG data.
ISDN was 22.22% (4/18) and the AE incidence of XXK was
12.50% (2/16). Another study [34] reported that of the AE
incidence of ISDN was 13.33% (4/30) and the AE incidence
of XXK was 0% (0/30). The third study [33] reported that
the AE incidence of ISDN was 28.79% (19/66) and the AE
incidence of XXKwas 0% (0/66). The last study [31] reported
no AE for all participants. The overall AE incidence of XXK
at 1.30% (2/155) was lower than that of ISDN at 17.42%
(27/155).
4. Discussion
This study provides a PRISMA-compliant systematic review
and meta-analysis based on the RCTs of XXK and ISDN to
evaluate the eﬃcacy in treating angina pectoris. Seven RCTs
with 550 participants were found eligible and thus included.
Overall ORs of SYMPTOMS and ECG were 4.11 and 2.37,
respectively and were statistically significant (P < 0.05). Sub-
group analysis, sensitivity analysis, and metaregression on
various parameters showed this positive evidence to be roz-
bust. This meta-analysis found that XXK seems to be more
eﬀective than ISDN in treating angina pectoris.
This systematic review is comprehensive, reliable, and
PRISMA-compliant. In this meta-analysis, (a) a comprehen-
sive search for RCTs published between 1989 and 2011 were
performed; (b) only the studies with XXK and ISDN as
single-drug interventions were included; (c) subgroup anal-
ysis, sensitivity analysis, and metaregression were performed
according to the basic characteristics of included studies; (d)
publication bias was assessed not only by funnel plots but
also by the Begg’s test and Egger’s test.
This study indicated XXK seems to bemore eﬀective than
ISDN in treating angina pectoris. The active components of
XXK are steroidal saponin glycosides, among which Saponin
DP 1–8 is a major component [37]. XXK were able to
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(a) maintain the activity of Ca2+-ATP enzyme and Na+-
K+-ATP enzyme through free radicals removal; (b) protect
myocardial cells from ischemia and maintain the integrity
of myocardial cell membrane; (c) protect myocardial cells
through dilated coronary arteries, reduced coronary resis-
tance, increased coronary blood flow, improved blood and
oxygen supply to myocardium; (d) improve myocardial
ischemia symptoms through reducing myocardial oxygen
consumption and enhancing tolerance of myocardium to
hypoxia [38, 39].
A major limitation of this systematic review, like other
systematic reviews on Chinese RCTs [16], is the quality
of included studies. Only 6.8% RCTs on 20 common dis-
eases published from January 1994 to June 2005 are authentic
RCTs conducted in China National Knowledge Infrastruc-
ture electronic database [40]. Most of the included studies
scored only 2 at the Jadad scale, which is a scale ranged
between 0 and 5. Neither allocation concealment nor blind-
ing was mentioned in the included studies. Four out of seven
included studies scored only 3 at theM scale (ranged between
1 and 7). Althoughwe found no statistically significant diﬀer-
ence in the eﬀect sizes between diﬀerent grades of study
quality, further updates of this systematic review should be
required to confirm the eﬃcacy of XXK over ISDN.
All studies included in this meta-analysis did not report
full outcome measure data. They only reported the results
based on the number of participants with diﬀerent responses
to the treatments. Moreover, the follow-up period of all stud-
ies was only 28 days; thus, tolerance of ISDN over time would
not be estimated. Tolerance of ISDN was not adequately
considered in past meta-analyses of (even) western medi-
cine RCTs.
This systematic review included the studies comparing
XXK and ISDN and excluded the studies with combined
drugs. The dosages of XXK were in accordance with recom-
mended dosages (two pills each time, three times a day) of
the manufacturer. Daily dosages of ISDN ranged from 30mg
to 60mg. The guideline of ACC/AHA 2002 suggested the oral
dosage range of ISDN to be 5–80mg each time twice or three
times a day. A previous study [41] found that high dosages of
ISDN were not better than low dosages of ISDN in treating
angina pectoris. The interpretation of the trial results in this
systematic reviewwould not be complicated by the combined
use of DSP or ISDN with other drugs.
Incidence of AEs due to XXK (1.30%) was lower than
those due to ISDN (17.42%). All seven included studies did
not report AEs in a standard format. Three studies did not
report AEs at all. Thus, the safety of XXK could not be thoro-
ughly evaluated although it is well appreciated in the research
community that RCTs should report AEs properly [42].
5. Conclusion
The meta-analysis of eligible but limited RCTs demonstrates
that XXK seems to be more eﬀective than ISDN in treating
angina pectoris. Further RCTs of high quality are warranted
to be conducted for update of the results of this meta-
analysis.
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